CN105671179A - Application of serum microRNA in liver cancer diagnosis and diagnosis kit - Google Patents

Application of serum microRNA in liver cancer diagnosis and diagnosis kit Download PDF

Info

Publication number
CN105671179A
CN105671179A CN201610158542.0A CN201610158542A CN105671179A CN 105671179 A CN105671179 A CN 105671179A CN 201610158542 A CN201610158542 A CN 201610158542A CN 105671179 A CN105671179 A CN 105671179A
Authority
CN
China
Prior art keywords
mir
hsa
combination
liver
microrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610158542.0A
Other languages
Chinese (zh)
Other versions
CN105671179B (en
Inventor
庄诗美
林雪嘉
方坚鸿
郭智伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kuanran Biomedical Technology Co ltd
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CN201610158542.0A priority Critical patent/CN105671179B/en
Publication of CN105671179A publication Critical patent/CN105671179A/en
Application granted granted Critical
Publication of CN105671179B publication Critical patent/CN105671179B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a hepatocellular carcinoma diagnosis marker combination composed of serum microRNA and a kit comprising the marker combination. The hepatocellular carcinoma diagnosis marker combination comprises following microRNA: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c and hsa-miR-192. The hepatocellular carcinoma diagnosis marker combination and the kit can be used for liver cancer diagnosis.

Description

The application of serum microRNA in diagnosing cancer of liver and diagnostic kit
Technical field
The invention belongs to biomedical diagnostic field, it is specifically related to the diagnosing cancer of liver combination being made up of serum microRNA, described serum microRNA comprises hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c, hsa-miR-192, and for the test kit of diagnosing cancer of liver and application thereof.
Background technology
Primary hepatocarcinoma is high incidence common within the scope of the world, the malignant tumour of high lethality rate, and wherein hepatocellular carcinoma (being called for short liver cancer, HepatocellularCarcinoma, HCC) accounts for more than the 90% of primary hepatocarcinoma. " whole world cancer report 2014 " that the World Health Organization delivers points out, within 2012, global liver cancer new cases rank the 5th of malignant tumour, and its lethality rate then occupies the 2nd, and wherein China's liver cancer new is sent out and death all accounts for the half of whole world case. Owing to lacking effective examination means, it is in late period when causing the liver cancer patient of 60%-70% to be diagnosed, has missed radical-ability cutting opportunity. Visible, early diagnosis, early treatment increases liver cancer patient survival rate, reduces the most effective approach of mortality of liver cancer.
The process that the generation development process of liver cancer is that one multifactor, multistage, multistep are rapid. The liver cirrhosis that any reason causes is the most common Hazard Factor of liver cancer. In Asia, hepatitis, liver cirrhosis that chronic HBV (HBV) causes are the topmost risk factors of induced hepatocellular carcinoma. Most liver cancer patient, with hepatitis and liver cirrhosis pathological change, is being gone through hepatitis, after the liver cirrhosis stage, is finally being developed into liver cancer, and people are referred to as " liver cancer trilogy ". It is estimated that China's hepatitis B carriers quantity nearly 1.2 hundred million, wherein 20% will develop into chronic hepatitis B patient, and the chronic hepatitis B patient of 15%-40% then will be further development of liver cirrhosis. Therefore, liver cancer high risk population is carried out long term monitoring, find early and early warning early hepatocarcinoma, be convenient to determine individuation control prece targetedly, delay even to prevent the generation of liver cancer, be conducive to improving patient's life quality.
Current clinical on mainly through serum alpha-fetoprotein (AFP) detection or imaging examination examination liver cancer. Although AFP is extensively for Hepatocarcinoma screening, but the susceptibility of its detection liver cancer is not high enough: go out in the patient of liver cancer in clinical diagnosis, and the AFP level of about 35-60% liver cancer patient is still lower than warning value (20ng/ml); Susceptibility in subclinical liver cancer is then only 14-40%. Although the imaging examination methods such as ultrasonic, CT, MRI can supplementing as AFP detection, but owing to following up a case by regular visits to examination for a long time, then expense is expensive, and the recall rate of these methods depends on the experience of tumour size and operator, the situation thus mistaken diagnosis may occur, failing to pinpoint a disease in diagnosis.Thus, it was discovered that new hypersensitivity, high specific, and the cheap hepatocarcinoma early diagnosis mark being easy to again detection has important clinical meaning.
MicroRNA is the endogenous property small molecules non-coding RNA that a class is extensively present in eukaryote, and length is 18-24 Nucleotide (nt). MicroRNA suppresses the expression of target gene by transcribing rear level, and regulating cell breaks up, breed, the vital movement such as die of withering, and plays a significant role in the multiple physiology such as fetal development, organism metabolism, disease development and pathologic process. In recent years, researchist detects microRNA in the multiple body fluid such as blood, saliva, urine, it is proposed to the concept of circulation microRNA. The humoral specimens such as blood are easy to obtain, and the clinical property grasped is strong and traumatic little, and the microRNA good stability that circulates, and detection is convenient, and therefore, circulation microRNA has the potential as the non-invasive biomarker of the diseases such as tumour, is applicable to high risk population's examination.
Recently research is pointed out, liver cancer patient has different circulation microRNA express spectras from non-liver cancer comparison. Such as, level in liver cancer patient and HBV hepatitis serum of miR-21, miR-122, miR-223 is all higher than healthy people; And the miR-21 raised in liver cancer patient blood plasma lowers after patient's surgical blanking; The people such as Li are by the detection 513 individual serum microRNA express spectras of example, it is determined that distinguish HBV hepatitis and healthy people and the liver cancer patient sort merge with health people; The people such as Zhou have detected the level of nearly thousand parts of plasma specimen microRNA, find by miR-122, miR-192, miR-21, miR-223, miR-26a, the sort module that seven circulation microRNA such as miR-27a and miR-801 are formed, liver cancer and all non-liver cancer colonies summation (comprising healthy people, hepatitis, liver cirrhosis patient) can be distinguished, and the liver cancer of diagnosable AFP negative. These research prompting circulation microRNA is as the potential of diagnosing cancer of liver mark.
But still have the following disadvantages as the research of diagnosing cancer of liver mark about circulation microRNA at present: the research of (1) major part just picks the microRNA alternatively index expressing imbalance at liver cancer tissue of forefathers' report, it is possible to cannot objectively respond the situation of circulation microRNA comprehensively; (2) part research sample size is few, lacks multicenter checking; (3) comparison arranges imperfect, it is difficult to illustrate that the mark determined is the special diagnosis marker of liver cancer. Therefore, still it is necessary to find to have the hepatocarcinoma early diagnosis mark of clinical value at present, for the monitoring of liver cancer high risk population, thus the early stage small liver cancer of early warning early, it is convenient to clinician and takes appropriate prophylactico-therapeutic measures in time.
In the patent application 201410623463.3 of Zhongshan University, disclosing by hsa-miR-29a, hsa-miR-29c, hsa-miR-133a, hsa-miR-143, hsa-miR-145, hsa-miR-192 and hsa-miR-505 diagnosing cancer of liver mark that totally seven microRNA form, it has the features such as early diagnosis susceptibility height, specificity be good. However, still there is the demand providing the combination of other liver cancer analyzing and diagnosing markers in this area.
Summary of the invention
It is an object of the invention to for the technical problem solved above, it is provided that a kind of easy and simple to handle, can the diagnosing cancer of liver mark of efficient diagnosis liver cancer.
For realizing above-mentioned technical purpose, the present invention provides a kind of diagnosing cancer of liver mark, and described diagnosing cancer of liver mark comprises the nucleic acid molecule encoding the combination of following microRNA molecule respectively:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
In a preferred embodiment, the level of described microRNA in liver cancer patient blood serum is higher than healthy people, hepatitis B carriers, chronic hepatitis B patient or liver cirrhosis patient. Preferably, described liver cancer is primary hepatocyte hepatocarcinoma.
On the other hand, present invention also offers the microRNA molecule for diagnosing cancer of liver and combine, it comprises following microRNA and combines:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
In a preferred embodiment, the level of described microRNA in liver cancer patient blood serum is higher than healthy people, hepatitis B carriers, chronic hepatitis B patient or liver cirrhosis patient. Preferably, described liver cancer is primary hepatocyte hepatocarcinoma.
Specifically, the present invention obtains above-mentioned four kinds of diagnosing cancer of liver combinations being made up of serum microRNA by following step:
1. the candidate serum microRNA of liver cancer patient and chronic hepatitis B patient difference is screened by high-throughput qPCRArray;
2. real-time fluorescence quantitative PCR checking candidate serum microRNA;
3. establish in training group be made up of healthy people, hepatitis, liver cirrhosis, liver cancer patient and can distinguish liver cancer and compare the serum microRNA of (comprising health people, hepatitis and liver cirrhosis patient) with non-cancer and combine;
4. the effect of the serum microRNA combined diagnosis liver cancer established at two individual authentication group verification steps 3;
5. the serum microRNA that analytical procedure 3 is established is combined in small liver cancer, the BCLC diagnosis effect in early days and in the liver cancer patient of AFP negative.
Experimental result is analyzed and relevant statistics display: in above-mentioned steps 1, contriver is screened by high-throughput qPCRArray and determines 19 candidate microRNA, and demonstrates the level of 19 candidate microRNA in liver cancer patient blood serum in step 2 and all raise. Have detected the level of candidate microRNA in training group (sample size is 257 parts) further, and establish and distinguish the optimum serum microRNA that compares with non-cancer of liver cancer and combine. And then in independent checking group 1 and checking group 2 (sample size is respectively 352,139 parts), demonstrate this serum microRNA combine and can distinguish liver cancer and compare with non-cancer. Meanwhile, contriver finds to compare traditional Hepatocarcinoma screening means, and such as AFP, serum microRNA is combined in small liver cancer, BCLC has better diagnosis effect in early days and in the liver cancer patient of AFP negative.
In yet another aspect, the invention also discloses a kind of diagnostic kit for diagnosing cancer of liver, comprise the reagent being respectively used to detect following microRNA molecule level in serum:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
In one embodiment, the described reagent for detecting microRNA molecule level in serum is real-time fluorescence quantitative PCR related reagent.
In another preferred embodiment, described diagnostic kit also comprises serum RNA extraction system and reverse transcription system. In preferred embodiments, this test kit also comprises the analytical procedure of the suffering from hepatic cancer for assessment of whether.
In a preferred embodiment, described diagnostic kit comprises the LNA Mdification primer that can be used for detecting following microRNA level:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
Preferably, the described reagent being combined in serum level for detecting microRNA molecule is real-time fluorescence quantitative PCR related reagent.
Preferred, described diagnostic kit also comprises the LNA Mdification primer of detection external source with reference to NC67. By external source with reference to NC67 calibration, obtain the level 2 of above-mentioned target gene in serum specimen to be checked-ΔCt(Δ Ct=Cttaget-Ctreference). According to microRNA threshold value by detection sample microRNA level respectively assignment be 1 or 0, it is achieved discretize.
Further, respectively according to logistic regression methods analyst serum microRNA combined evaluation person to be measured whether suffering from hepatic cancer:
1) one: Logit (p=HCC)=-0.333-0.578*hsa-miR-193a-5p-0.531*hsa-miR-143-0.692*hsa-miR-145 is combined;
2) two: Logit (p=HCC)=-0.343-0.407*hsa-miR-193a-5p-0.595*hsa-miR-29a-0.706*hsa-miR-133a-0.480*hsa-miR-505 is combined;
3) three: Logit (p=HCC)=-0.326-0.419*hsa-miR-193a-5p-0.347*hsa-miR-29a-0.354*hsa-miR-29c-0.654*hsa-miR-145-0.423*hsa-miR-192 is combined;
4) four: Logit (p=HCC)=-0.355-0.171*hsa-miR-193a-5p-0.338*hsa-miR-29a-0.531*hsa-miR-133a-0.511*hsa-miR-145-0.462*hsa-miR-192-0.393*hsa-m iR-505 is combined.
Wherein, hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c, hsa-miR-192 are the numerical value after corresponding serum microRNA detection level discretize, and taking Logit (p=HCC)=0.5 as diagnostic threshold, it is diagnosed as liver cancer higher than 0.5, it is diagnosed as non-liver cancer lower than 0.5. Described diagnostic kit can be applicable to diagnosing cancer of liver.
The serum microRNA of the present invention combines the superiority being used for liver cancer detection and early diagnosis and is: (1) sample is easier to obtain, and the clinical property grasped is stronger and traumatic less, and serum microRNA stability is better, and it is more convenient to detect;(2) experimental technique is very ripe, and testing process is easier, be easy to repetition, all can complete by common technician; (3) the present invention adopts the checking of high flux screening, multicenter and studies in high risk population's sample, the effect and the diagnostic kits that combine serum microRNA have carried out comprehensive assessment, the application of above methods and strategies ensure that the potential using value of the present invention in liver cancer clinical diagnosis, and provides referential methods and strategies for the development of other diseases biomarker; (4) serum microRNA diagnosing liver cancer test kit can reflect the morbid state of liver cancer patient more in time, avoids numerous and diverse detection, saves time human cost, is convenient to clinician and takes personalized control prece in time.
Accompanying drawing explanation
Fig. 1 is the ROC curve figure of the embodiment of the present invention 4,5 in training group, checking group. Specifically, in training group (A), checking group 1 (B) and checking group 2 (C), serum microRNA combination and AFP distinguish liver cancer and compare (upper figure) and the ROC curve figure of high risk population's (figure below) with non-cancer.
Fig. 2 is the ROC curve figure of the embodiment of the present invention 6 in small liver cancer patient (tumour≤3cm). Specifically, training group (A), checking group 1 (B), checking group 2 (C) and training group combine with serum microRNA in all checking groups (D) and AFP differentiation small liver cancer patient compares (left figure) and the ROC curve figure of high risk population (right figure) with non-cancer.
Fig. 3 is the ROC curve figure of the embodiment of the present invention 7 in different B CLC by stages liver cancer patient. Specifically, serum microRNA combination and AFP distinguish BCLC0+A phase (A), BCLCB phase (B) or BCLCC phase (C) liver cancer patient and compare (upper figure) and the ROC curve figure of high risk population's (figure below) with non-cancer.
Fig. 4 is the ROC curve figure of the embodiment of the present invention 8 in AFP negative liver cancer patient (AFP≤20ng/ml). Specifically, training group (A), checking group 1 (B), checking group 2 (C) and training group combine differentiation AFP negative liver cancer patient and compare (left figure) and the ROC curve figure of high risk population (right figure) with non-cancer with serum microRNA in all checking groups (D).
Embodiment
For making the present invention easier to understand, below in conjunction with the drawings and specific embodiments, set forth the present invention further. It will be understood that these embodiments are only for illustration of the present invention, and it are not used in and limit the scope of the invention; Described accompanying drawing is also only schematic, is considered as non-limiting.
Embodiment 1: the collection of serum specimen and preparation
Contriver acquires the blood preparation of healthy people (HC), hepatitis B carriers (IHC), chronic hepatitis B patient (CHB), liver cirrhosis patient (LC) and liver cancer patient (HCC) August in August, 2009 to 2014 year, these crowds meet into group standard (table 1), and the principle according to sex, age-matched, setting liver cancer and control group sample thereof.
Training group: 257 parts of serum specimens of healthy people (51 example), chronic hepatitis B patient (51 example), liver cirrhosis patient (47 example) and liver cancer patient (108 example) that March in August, 2009 to 2012 year gathers.
352 parts of serum specimens of healthy people (60 example), chronic hepatitis B patient (68 example), liver cirrhosis patient (71 example) and liver cancer patient (153 example) that checking group 1:2012 gathers April in April to 2013 year.
139 parts of serum specimens of healthy people (48 example), hepatitis B carriers (42 example) and liver cancer patient (49 example) that checking group 2:2013 gathers August in May to 2013 year.
The Clinical symptoms of above-mentioned participation crowd is in table 2.
What table 1. participated in crowd enters group standard
Enter set condition with reference to hepatopathy research association of the U.S. (AASLD) practice guideline in 2009.
With reference to liver biopsy Metavir system.
Extract liver cancer patient people preoperative, healthy, hepatitis B carriers, chronic hepatitis B patient and each 4ml of liver cirrhosis patient peripheric venous blood, in dry heparin tube more than 4 DEG C of standing half hours. 400g subsequently, 4 DEG C of centrifugal 10min get supernatant, further 1800g, and 4 DEG C of centrifugal 10min get supernatant, obtain serum, save backup in-80 DEG C after packing.
The clinical pathologic characteristic of table 2. training group and checking group participant
Embodiment 2:qPCRArray and data analysis thereof
Choose that 6 liver cancer patients are preoperative and apart from lasts, 8 chronic hepatitis B patients check that the serum specimen in more than at least one years screens for qPCRArray. These patients are the male sex, and its age average, distribution are all without significant difference (table 3).
The sample clinical pathologic characteristic that table 3. is analyzed for qPCRArray
The present invention adopts AppliedBiosystems companyThe microRNA of ArrayHumanMicroRNA method screening liver cancer and chronic hepatitis B difference, detects the level of 754 known mankind microRNA altogether. Concrete steps are see AppliedBiosystems website. The raw data obtained, after calibration, adopts SignificantAnalysisofMicroarray (SAM) analytical procedure to select difference microRNA, and final screening obtains 19 candidates microRNA (table 4) for subsequent authentication.
The candidate microRNA that table 4. the present invention adopts and external source are with reference to information
Exiqon company production code member
Embodiment 3: real-time fluorescence quantitative PCR detection training group sample microRNA level
1.1 serum RNA extract
The present invention adopts Trizol reagent to extract, and helps heavy method to obtain serum RNA through phenol/chloroform extracting and purifying, isopropanol precipitating, glycogen, and concrete steps are as follows:
1. get 200 μ l serum, preferably add and isopyknic it is mixed with cel-miR-67 (NC67, the double-stranded RNA designed by the ripe body sequence of the nematode miR-67 of homology is not had based on human genomic sequence, final concentration is 0.2nM, sequence is in table 4) Trizol lysate, fully vibration is mixed even, ice bath 15min.
2. adding 100 μ l precooling chloroforms, vibration is mixed even, 4 DEG C, the centrifugal 15min of 12000g.
3. shifting supernatant, add equal-volume precooling phenol/chloroform (1:1), vibration is mixed even, 4 DEG C, the centrifugal 10min of 14000g. And repeat this step once.
4. shifting supernatant, add equal-volume precooling chloroform, vibration is mixed even, 4 DEG C, the centrifugal 15min of 14000g.
5. shifting supernatant, it is preferable that add equal-volume Virahol and glycogen (final concentration is 200 μ g/ml), vibration is mixed even, 4 DEG C, the centrifugal 30min of 16000g.
6. carefully topple over supernatant, precipitate once by 1ml70% washing with alcohol, 4 DEG C, the centrifugal 10min of 16000g.
7. abandon supernatant, after ethanol volatilizees, add 10 μ lDEPC water dissolution, be placed in-80 DEG C and save backup.
1.2 real-time fluorescence quantitative PCRs (RT-qPCR)
The present invention preferably adopts UniversalcDNASynthesis Reverse Transcriptase kit, and the serum RNA of equity volume carries out reverse transcription. Further preferably adopting SYBRGreenqPCRmastermix test kit, to dilute the cDNA of 20 times as template, the primer that LNA modifies carries out RT-qPCR detection. Described Reverse Transcriptase kit, qPCR detection kit and LNA Mdification primer are all purchased from Exiqon company (Denmark).
By external source with reference to NC67 calibration, obtain the expression values 2 of target microRNA-ΔCt(Δ Ct=Cttaget-Ctreference). Result shows, and 19 candidate microRNA level in liver cancer patient blood serum all significantly raises.
Embodiment 4: determine in training group that optimum serum microRNA combines
By training group sample according to 19 microRNA separately detection level arrange from big to small, and value (then only getting once if any repetition values) successively, according to value, sample is judged to positive or negative class group, obtain the Sensitivity and Specificity of each value in conjunction with the set classification analysis of sample, draw ROC curve (ReceiverOperatingCharacteristicCurve) further. Searching makes the point that (susceptibility+specificity)/2 values reach maximum, and the expression numerical value of this some correspondence is the threshold value of microRNA discretize. Further by be more or less than threshold value sample respectively assignment be 1 or 0, it is achieved discretize, for further model construction. MicroRNA discretize threshold value (table 4) that the present invention adopts will be used for training the discretize of corresponding microRNA data in group, checking group, thus continuous variable is changed into two classified variables.
Modeling result shows, and below combines and diagnosing liver cancer is had good result:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
Its formula assessing whether suffering from hepatic cancer is respectively:
(1) one: Logit (p=HCC)=-0.333-0.578*hsa-miR-193a-5p-0.531*hsa-miR-143-0.692*hsa-miR-145 is combined;
(2) two: Logit (p=HCC)=-0.343-0.407*hsa-miR-193a-5p-0.595*hsa-miR-29a-0.706*hsa-miR-133a-0.480*hsa-miR-505 is combined;
(3) three: Logit (p=HCC)=-0.326-0.419*hsa-miR-193a-5p-0.347*hsa-miR-29a-0.354*hsa-miR-29c-0.654*hsa-miR-145-0.423*hsa-miR-192 is combined;
(4) four: Logit (p=HCC)=-0.355-0.171*hsa-miR-193a-5p-0.338*hsa-miR-29a-0.531*hsa-miR-133a-0.511*hsa-miR-145-0.462*hsa-miR-192-0.393*hsa-m iR-505 is combined.
Wherein, hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c, hsa-miR-192 are the numerical value after corresponding serum microRNA detection level discretize.
Aforesaid combination can be distinguished liver cancer in training group and compare with non-cancer or high risk population, there is good diagnosing cancer of liver effect, show the AUC that serum microRNA combines all be greater than AFP20 or AFP400 (using 20 or 400ng/ml as AFP threshold value) AUC (Figure 1A).
Embodiment 5: the effect verifying serum microRNA combined diagnosis liver cancer in checking group
The serum microRNA established in training group combines and is used to checking group diagnosing liver cancer. Equally, Trizol extraction and real-time fluorescence quantitative PCR detection method is adopted to test.Described it is combined in checking group 1,2 still to distinguish liver cancer compare with non-cancer or high risk population, there is good diagnosing cancer of liver effect, show that the AUC that serum microRNA combines all is greater than the AUC (in Fig. 1 B, C) of AFP20 or AFP400.
Embodiment 6: the diagnosis effect that serum microRNA is combined in small liver cancer patient (tumour≤3cm)
The present invention further demonstrates serum microRNA and combines the effect with well diagnosis small liver cancer. In training group, checking group 1, checking group 2, the AUC of these combined diagnosis small liver cancers is all significantly greater than AFP; Training group is same with three checking group case combined analysis results show these combinations distinguish small liver cancers compare with non-cancer or the AUC of high risk population much larger than AFP20 or AFP400 (Fig. 2), be respectively:
Combination one: 0.815vs0.729 or 0.616,0.813vs0.711 or 0.615;
Combination two: 0.833vs0.729 or 0.616,0.824vs0.711 or 0.615;
Combination three: 0.839vs0.729 or 0.616,0.819vs0.711 or 0.615;
Combination four: 0.839vs0.729 or 0.616,0.835vs0.711 or 0.615.
Embodiment 7: serum microRNA is combined in the different B CLC diagnosis effect in liver cancer patient by stages
Serum microRNA is combined in different B CLC all has preferably diagnosis effect in liver cancer patient by stages, the AUC of these combinations is significantly greater than the AUC of AFP, especially in the BCLC0+A phase, namely BCLC is early stage, the advantage of combination is more obvious: taking all non-cancer comparison/high risk population as comparison, in BCLC0+A phase diagnosing cancer of liver, the AUC of aforesaid combination is respectively: combination one: 0.805/0.802; Combination two: 0.821/0.811; Combination three: 0.805/0.785; Combination four: 0.823/0.819; AFP20 or AFP400 is then respectively 0.735/0.709 or 0.649/0647 (Fig. 3).
Embodiment 8: the diagnosis effect that serum microRNA is combined in AFP negative (AFP≤20ng/ml) liver cancer patient
Serum microRNA is combined in AFP negative liver cancer patient to have good diagnosis effect equally. Taking all non-cancer comparison/high risk population as comparison, aforesaid combination is respectively at the AUC (Fig. 4) of the prediction AFP negative liver cancer of training group, checking group 1, each group of checking group 2 and all center combination:
Combination one: 0.819/0.824,0.803/0.816,0.883/0.831 and 0.819/0.818;
Combination two: 0.762/0.763,0.782/0.784,0.789/0.731 and 0.780/0.769;
Combination three: 0.830/0.818,0.799/0.787,0.858/0.782 and 0.819/0.795;
Combination four: 0.844/0.847,0.797/0.801,0.892/0.865 and 0.827/0.824.
Embodiment 9: the making of serum microRNA test kit
Test kit of the present invention is used for diagnosing cancer of liver, especially early hepatocarcinoma, by serum RNA extraction system, reverse transcription system, real-time fluorescence quantitative PCR system, primer system and whether for assessment of the logistic regression analysis method of suffering from hepatic cancer forms.
In the serum RNA extraction system of described test kit, contriver adopts Trizol reagent to extract, and helps heavy method to obtain serum RNA through phenol/chloroform extracting and purifying, isopropanol precipitating, glycogen. Contriver adopts primer that a series of Exiqon company LNA modifies as the primer system of described test kit, for detecting following molecule: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c, hsa-miR-192 and NC67 (external source reference).
In real-time fluorescence quantitative PCR system, contriver adopts the Reverse Transcriptase kit of Exiqon company and SYBRGreenqPCRmastermix test kit to detect. Further respectively according to logistic regression methods analyst serum microRNA combined evaluation person to be measured whether suffering from hepatic cancer:
Combination one: Logit (p=HCC)=-0.333-0.578*hsa-miR-193a-5p-0.531*hsa-miR-143-0.692*hsa-miR-145;
Combination two: Logit (p=HCC)=-0.343-0.407*hsa-miR-193a-5p-0.595*hsa-miR-29a-0.706*hsa-miR-133a-0.480*hsa-miR-505;
Combination three: Logit (p=HCC)=-0.326-0.419*hsa-miR-193a-5p-0.347*hsa-miR-29a-0.354*hsa-miR-29c-0.654*hsa-miR-145-0.423*hsa-miR-192;
Combination four: Logit (p=HCC)=-0.355-0.171*hsa-miR-193a-5p-0.338*hsa-miR-29a-0.531*hsa-miR-133a-0.511*hsa-miR-145-0.462*hsa-miR-192-0.393*hsa-m iR-505.
Wherein, hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c, hsa-miR-192 are the numerical value after corresponding serum microRNA detection level discretize. Taking Logit (p=HCC)=0.5 as diagnostic threshold, it is liver cancer patient higher than 0.5, it is non-liver cancer patient lower than 0.5.

Claims (10)

1. a diagnosing cancer of liver mark, it comprises the nucleic acid molecule encoding the combination of following microRNA molecule respectively:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
2. diagnosing cancer of liver mark according to claim 1, the level of wherein said microRNA in liver cancer patient blood serum is higher than healthy people, hepatitis virus carrier, chronic hepatitis patient or liver cirrhosis patient.
3., according to the diagnosing cancer of liver mark of claim 1 or 2, wherein said liver cancer is primary hepatocyte hepatocarcinoma.
4. microRNA molecule for diagnosing cancer of liver combines, and it comprises following microRNA and combines:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
5. microRNA molecule according to claim 4 combination, it is characterised in that, the level of the microRNA in described microRNA combination in liver cancer patient blood serum is higher than healthy people, hepatitis virus carrier, chronic hepatitis patient or liver cirrhosis patient.
6. microRNA molecule according to claim 4 or 5 combines, and wherein said liver cancer is primary hepatocyte hepatocarcinoma.
7., for the diagnostic kit of diagnosing cancer of liver, it comprises the reagent being respectively used to detect following microRNA molecule and being combined in serum level:
1) combination one: hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145;
2) combination two: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-505;
3) combination three: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-29c, hsa-miR-145, hsa-miR-192;
4) combination four: hsa-miR-193a-5p, hsa-miR-29a, hsa-miR-133a, hsa-miR-145, hsa-miR-192, hsa-miR-505.
Preferably, the described reagent being combined in serum level for detecting microRNA molecule is real-time fluorescence quantitative PCR related reagent.
8. diagnostic kit according to claim 7, its logistic regression formula is respectively:
1) one: Logit (p=HCC)=-0.333-0.578*hsa-miR-193a-5p-0.531*hsa-miR-143-0.692*hsa-miR-145 is combined;
2) two: Logit (p=HCC)=-0.343-0.407*hsa-miR-193a-5p-0.595*hsa-miR-29a-0.706*hsa-miR-133a-0.480*hsa-miR-505 is combined;
3) three: Logit (p=HCC)=-0.326-0.419*hsa-miR-193a-5p-0.347*hsa-miR-29a-0.354*hsa-miR-29c-0.654*hsa-miR-145-0.423*hsa-miR-192 is combined;
4) four: Logit (p=HCC)=-0.355-0.171*hsa-miR-193a-5p-0.338*hsa-miR-29a-0.531*hsa-miR-133a-0.511*hsa-miR-145-0.462*hsa-miR-192-0.393*hsa-m iR-505 is combined;
Wherein, hsa-miR-193a-5p, hsa-miR-143, hsa-miR-145, hsa-miR-29a, hsa-miR-133a, hsa-miR-505, hsa-miR-29c, hsa-miR-192 are the numerical value after corresponding serum microRNA detection level discretize, and taking Logit (p=HCC)=0.5 as diagnostic threshold, it is diagnosed as liver cancer higher than 0.5, it is diagnosed as non-liver cancer lower than 0.5.
9. according to the diagnostic kit of claim 7 or 8, it is characterised in that, described diagnostic kit is applied to diagnosing cancer of liver. Preferably, described liver cancer is primary hepatocyte hepatocarcinoma.
10. according to the application in diagnosing cancer of liver of the diagnostic kit of claim 7-9 arbitrary.
CN201610158542.0A 2016-03-18 2016-03-18 application of serum microRNA in liver cancer diagnosis and diagnosis kit Active CN105671179B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610158542.0A CN105671179B (en) 2016-03-18 2016-03-18 application of serum microRNA in liver cancer diagnosis and diagnosis kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610158542.0A CN105671179B (en) 2016-03-18 2016-03-18 application of serum microRNA in liver cancer diagnosis and diagnosis kit

Publications (2)

Publication Number Publication Date
CN105671179A true CN105671179A (en) 2016-06-15
CN105671179B CN105671179B (en) 2019-12-17

Family

ID=56215197

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610158542.0A Active CN105671179B (en) 2016-03-18 2016-03-18 application of serum microRNA in liver cancer diagnosis and diagnosis kit

Country Status (1)

Country Link
CN (1) CN105671179B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937519A (en) * 2017-10-31 2018-04-20 温州医科大学 A kind of serological specificity biomarker and screening technique and application for diagnosing primary liver cancer
CN111349704A (en) * 2020-03-17 2020-06-30 河北医科大学第三医院 Diagnostic product and therapeutic composition for liver cancer
CN112553340A (en) * 2020-12-30 2021-03-26 武汉友芝友医疗科技股份有限公司 Application of ncRNA in liver cancer diagnosis, liver cancer diagnosis reagent, kit and diagnosis system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101386848A (en) * 2008-08-12 2009-03-18 南京大学 MiRNA with cell corpuscule as vector and preparation research approach thereof and application
CN104372087A (en) * 2014-11-06 2015-02-25 中山大学 Liver cancer diagnosis markers composed of serum microRNA (microribonucleic acid) and diagnosis kit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101386848A (en) * 2008-08-12 2009-03-18 南京大学 MiRNA with cell corpuscule as vector and preparation research approach thereof and application
CN104372087A (en) * 2014-11-06 2015-02-25 中山大学 Liver cancer diagnosis markers composed of serum microRNA (microribonucleic acid) and diagnosis kit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALESSANDRO SALVI等: "effects of miR-193a and sorafenib on hepatocellular carcinoma cells", 《MOLECULAR CANCER》 *
童明庆主编: "《临床检验诊断学》", 31 October 2002 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937519A (en) * 2017-10-31 2018-04-20 温州医科大学 A kind of serological specificity biomarker and screening technique and application for diagnosing primary liver cancer
CN107937519B (en) * 2017-10-31 2021-11-02 温州医科大学 Serum specific biomarker for diagnosing primary liver cancer, screening method and application
CN111349704A (en) * 2020-03-17 2020-06-30 河北医科大学第三医院 Diagnostic product and therapeutic composition for liver cancer
CN112553340A (en) * 2020-12-30 2021-03-26 武汉友芝友医疗科技股份有限公司 Application of ncRNA in liver cancer diagnosis, liver cancer diagnosis reagent, kit and diagnosis system
CN112553340B (en) * 2020-12-30 2021-09-24 武汉友芝友医疗科技股份有限公司 Application of ncRNA in liver cancer diagnosis, liver cancer diagnosis reagent, kit and diagnosis system

Also Published As

Publication number Publication date
CN105671179B (en) 2019-12-17

Similar Documents

Publication Publication Date Title
CN104372087B (en) The diagnosing cancer of liver mark being made up of serum microRNA and diagnostic kit
CN105603101A (en) Application of system for detecting expression quantity of eight miRNAs in preparation of product for diagnosing or assisting in diagnosing hepatocellular carcinoma
WO2017202185A1 (en) Peripheral blood gene marker for screening benign and malignant small pulmonary nodules and use thereof
CN109576370A (en) Biomarker and detection kit for Diagnosis of Bladder and recurrence monitoring
CN105518154B (en) Brain cancer detection
CN114317745B (en) Application of exosomes ARPC5, ERI3 and the like in lung cancer diagnosis
CN105671179A (en) Application of serum microRNA in liver cancer diagnosis and diagnosis kit
CN104293919B (en) A kind of SNP mark relevant to Non-smoking females lung cancer auxiliary diagnosis and application thereof
CN106119347B (en) The primer and kit of colorectal cancer transfer detection based on serum exosomal microRNAs
CN104450702B (en) A kind of Serum miRNA biomarker composition and application
CN105671178A (en) Serum microRNA liver cancer diagnosis marker and kit
TWI758670B (en) Health risk assessment method
CN104263723B (en) A kind of low frequency related to primary lung cancer auxiliary diagnosis penetrance genetic marker high and its application
CN104278100B (en) MiRNA-188 is preparing the purposes in diagnostic reagent as tagged molecule
CN104975075A (en) System and method used for detection of IgA nephropathy and establishment of the method
CN115820857B (en) Kit for identifying gastric precancerous lesions and gastric cancer and diagnosing gastric cancer
CN109182520B (en) Cervical cancer and precancerous lesion detection kit and application thereof
CN104313142B (en) MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule
CN104313145B (en) MiRNA-30e is preparing the purposes in diagnostic reagent as tagged molecule
CN103866012A (en) Identified mmu-miR-217-5p capable of detecting toxoplasma gondii infection
CN116377062A (en) Application of reagent for detecting circular RNA hsa_circ_0033144 in preparation of gastric cancer diagnosis product
CN107043810A (en) A kind of primer sets and detection method for being used to detect colorectal cancer
CN106520925A (en) Primer group for detecting esophagus cancer, and detection method
CN103866011A (en) Identified mmu-miR-712-3p capable of detecting toxoplasma gondii infection
CN103865928A (en) Identified mmu-miR-511-5p capable of detecting toxoplasma gondii infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220302

Address after: 201805 Room 201, zone a, floor 2, building 1, No. 4997, Bao'an highway, Anting Town, Jiading District, Shanghai

Patentee after: Koran biomedical technology (Shanghai) Co.,Ltd.

Address before: 510275 No. 135 West Xingang Road, Guangdong, Guangzhou

Patentee before: SUN YAT-SEN University

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230207

Address after: Room 701-8, Building 1, Zone A, Huaihai Bio-pharmaceutical Industrial Park, No. 10, Zhujiang East Road, High-tech Industrial Development Zone, Xuzhou City, Jiangsu Province, 221116

Patentee after: Jiangsu kuanran Biomedical Technology Co.,Ltd.

Address before: 201805 Room 201, zone a, floor 2, building 1, No. 4997, Bao'an highway, Anting Town, Jiading District, Shanghai

Patentee before: Koran biomedical technology (Shanghai) Co.,Ltd.